TORONTO, ON, Canada -- October 12, 2021 --
InvestorsHub NewsWire -- Cybin
Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin"
or the "Company"), a biotechnology company focused
on progressing psychedelic therapeutics, today announced that it
has filed an international patent application related to methods
for the delivery of psychedelic medications by inhalation and
devices for performing those methods.
The application, governed by the Patent Cooperation Treaty
("PCT"), brings the potential to obtain patent coverage in 153
countries.
The Company believes that the delivery of psychedelic
medications using inhalation may overcome key obstacles encountered
by traditional oral drug administration. Specifically, the Company
expects inhalation delivery to facilitate optimized psychedelic
session timing compared to oral administration of the same
compounds, lower doses of psychedelic therapeutics while preserving
efficacy, and providing health care providers with more control
during psychedelic sessions.
Filed in support of the Company's CYB004 pre-clinical development program, the PCT
filing serves to increase the Company's library of drug delivery
modalities directed to optimal delivery of psychedelics and further
strengthens Cybin's growing IP portfolio.
The PCT filing also includes support for future research
programs respecting various systems which seek to minimize negative
side effects in psychedelic psychotherapy patients, methods that
enable lower and sub-psychedelic doses without impacting treatment
efficacy and increasing the long-term efficacy of psychedelic
sessions.
"The continued progression of our research programs guides our
discovery of new molecules and differentiating treatment
approaches. Continued innovation, as demonstrated by our expanding
IP portfolio, positions Cybin as a leading innovator in the
development of putative psychedelic treatments for a variety of
mental health conditions," said Doug Drysdale, the company's
CEO.
About Cybin
Cybin is a leading biotechnology company focused on
progressing psychedelic
therapeutics by utilizing proprietary drug discovery
platforms, innovative drug delivery systems, novel formulation
approaches and treatment regimens for psychiatric disorders.
Cautionary Notes and Forward-Looking
Statements
Certain statements in this press release constitute
forward-looking information. All statements other than statements
of historical fact contained in this press release, including,
without limitation, statements regarding Cybin's future, strategy,
plans, objectives, goals and targets, and any statements preceded
by, followed by or that include the words "believe", "expect",
"aim", "intend", "plan", "continue", "will", "may", "would",
"anticipate", "estimate", "forecast", "predict", "project", "seek",
"should" or similar expressions or the negative thereof, are
forward-looking statements. Forward looking statements in this news
release include statements regarding the Company's development of
innovative drug delivery systems, novel formulation approaches and
potential treatment regimens for psychiatric disorders and
proprietary development strategy and development of medicinal
psychedelics with improved dosing efficacy and therapeutic indices
to address unmet medical needs.
These forward-looking statements are based on reasonable
assumptions and estimates of management of the Company at the time
such statements were made. Actual future results may differ
materially as forward-looking statements involve known and unknown
risks, uncertainties, and other factors which may cause the actual
results, performance, or achievements of the Company to materially
differ from any future results, performance, or achievements
expressed or implied by such forward-looking statements. Such
factors, among other things, include: implications of the COVID-19
pandemic on the Company's operations; fluctuations in general
macroeconomic conditions; fluctuations in securities markets;
expectations regarding the size of the psychedelics market; the
ability of the Company to successfully achieve its business
objectives; plans for growth; political, social and environmental
uncertainties; employee relations; the presence of laws and
regulations that may impose restrictions in the markets where the
Company operates; and the risk factors set out in the Company's
management's discussion and analysis for the three months ended
June 30, 2021 and the Company's listing statement dated November 9,
2020, which are available under the Company's profile
on www.sedar.com and with the U.S. Securities
and Exchange Commission on EDGAR at www.sec.gov.
Although the forward-looking statements contained in this news
release are based upon what management of the Company believes, or
believed at the time, to be reasonable assumptions, the Company
cannot assure shareholders that actual results will be consistent
with such forward-looking statements, as there may be other factors
that cause results not to be as anticipated, estimated or intended.
Readers should not place undue reliance on the forward-looking
statements and information contained in this news release. The
Company assumes no obligation to update the forward-looking
statements of beliefs, opinions, projections, or other factors,
should they change, except as required by law.
Cybin makes no medical, treatment or health benefit claims about
Cybin's proposed products. The U.S. Food and Drug Administration,
Health Canada or other similar regulatory authorities have not
evaluated claims regarding psilocybin, psychedelic tryptamine,
tryptamine derivatives or other psychedelic compounds or
nutraceutical products. The efficacy of such products has not been
confirmed by approved research. There is no assurance that the use
of psilocybin, psychedelic tryptamine, tryptamine derivatives or
other psychedelic compounds or nutraceuticals can diagnose, treat,
cure or prevent any disease or condition. Vigorous scientific
research and clinical trials are needed. Cybin has not conducted
clinical trials for the use of its proposed products. Any
references to quality, consistency, efficacy and safety of
potential products do not imply that Cybin verified such in
clinical trials or that Cybin will complete such trials. If Cybin
cannot obtain the approvals or research necessary to commercialize
its business, it may have a material adverse effect on Cybin's
performance and operations.
The Neo Exchange Inc. has neither approved nor disapproved
the contents of this news release and is not responsible for the
adequacy and accuracy of the contents herein.
Contacts
Investor Contacts:
Tim Regan/Scott Eckstein
KCSA Strategic Communications
Cybin@kcsa.com
Lisa M. Wilson
In-Site Communications, Inc.
lwilson@insitecony.com
Media Contact:
John Kanakis
Cybin Inc.
John@cybin.com
Cybin (AMEX:CYBN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cybin (AMEX:CYBN)
Historical Stock Chart
From Sep 2023 to Sep 2024